@article{de59f4b064b243cd8658ca409a2a4b59,
title = "Response to letter entitled: Re: Predictive ability of a drug-based score in advanced non-small cell lung cancer patients receiving first-line immunotherapy",
author = "A. Cortellini and M. Bersanelli and PINATO, \{David James\} and S. Buti",
note = "Funding Information: Dr Sebastiano Buti received honoraria as a speaker at scientific events and advisory role by Bristol-Myers Squibb (BMS), Pfizer; MSD, Ipsen, Roche, Eli-Lilly, AstraZeneca and Novartis. Dr Melissa Bersanelli received honoraria as a speaker at scientific events by Bristol-Myers Squibb (BMS), Novartis, AstraZeneca, and Pfizer and as a consultant for the advisory role by Novartis, BMS, and Pfizer; she also received fees for copyright transfer by Sciclone Pharmaceuticals and research funding by Seqirus UK, Pfizer, Novartis, BMS, AstraZeneca, Roche S.p.A., and Sanofi Genzyme. Dr David J Pinato received lecture fees from ViiV Healthcare, Bayer Healthcare and travel expenses from BMS and Bayer Healthcare; consulting fees for Mina Therapeutics, EISAI, Roche, AstraZeneca; received research funding (to institution) from MSD, BMS. Dr Alessio Cortellini received speaker fees and grant consultancies by AstraZeneca, MSD, BMS, Roche, Novartis, Istituto Gentili.",
year = "2021",
doi = "10.1016/j.ejca.2021.07.011",
language = "English",
volume = "155",
pages = "315--316",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd.",
}
SDG 3 Salute e benessere